Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma

Autor: Minneke J. Coenraad, Mark C. Burgmans, Maarten E. Tushuizen, Jelte J Schaapman, L.F. de Geus-Oei, D.R. Sudiono, O.M. van Delden, T.T.M. Oosterveer, R.B. Takkenberg, P. Hendriks
Přispěvatelé: CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Radiology and Nuclear Medicine, Cancer Center Amsterdam
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
medicine.medical_specialty
Cirrhosis
Carcinoma
Hepatocellular
Hepatocellular carcinoma
medicine.medical_treatment
Liver transplantation
Gastroenterology
Microwave ablation
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Stage (cooking)
Chemoembolization
Therapeutic
Aged
Retrospective Studies
Aged
80 and over
Interventional radiology
Science & Technology
MICROWAVE ABLATION
business.industry
Liver Neoplasms
Radiology
Nuclear Medicine & Medical Imaging
Radiofrequency ablation
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
Combined Modality Therapy
Drug eluting beads
Thermal ablation
Regimen
Treatment Outcome
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION
Oncology
Tumor progression
Catheter Ablation
Chemoembolization
business
Life Sciences & Biomedicine
Zdroj: European Journal of Radiology, 144. ELSEVIER IRELAND LTD
European journal of radiology, 144:110006. Elsevier Ireland Ltd
ISSN: 0720-048X
Popis: BACKGROUND: The combination treatment regimen of thermal ablation (TA) and transarterial chemoembolization (TACE) has gained a place in treatment of hepatocellular carcinoma (HCC) lesions > 3 cm unsuitable for surgery. Despite a high heterogeneity in the currently used treatment protocols, the pooled results of combined treatments seem to outperform those of TA or TACE alone. TACE preceding TA has been studied extensively, while results of the reverse treatment sequence are lacking. In this retrospective cohort study we compared the two treatment sequences. PATIENTS AND METHODS: 38 patients (median age: 68.5 yrs (range 40-84), male: 34, liver cirrhosis: 33, early stage HCC: 21, intermediate stage HCC: 17) were included in two tertiary referral centers, of whom 27 were treated with TA and adjuvant TACE (TA + TACE). The other 11 patients received TA with neoadjuvant TACE (TACE + TA). Overall survival (OS), time to progression (TTP) and local tumor progression (LTP) free survival were determined for the entire cohort and compared between the two treatment sequences. RESULTS: The median OS of all patients was 52.7 months and the median time to LTP was 11.5 months (censored for liver transplantation). No differences were found with respect to OS between the two treatment sequences. Median time to LTP for TACE + TA was 23.6 months and 8.1 months for TA + TACE (p = 0.19). DISCUSSION: No statistical differences were found for OS, TTP and time to LTP between patients treated with TA combined with neoadjuvant or adjuvant TACE. ispartof: EUROPEAN JOURNAL OF RADIOLOGY vol:144 ispartof: location:Ireland status: published
Databáze: OpenAIRE
Externí odkaz: